文献速递白血病

真实世界中接受帕纳替尼治疗的慢性髓性白血病患者的管理:意大利药品管理局(AIFA)监测登记处的回顾性分析

Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA).
PubMed 文献 · Br J Haematol · 2022-07-29

通过意大利药品管理局(AIFA)监测登记处,对2015年2月至2020年12月纳入帕纳替尼登记处的666例慢性髓性白血病(CML)患者进行回顾性分析,其中慢性期515例、加速期50例、急变期101例。中位随访14.4个月,136例(20.4%)因不良事件(AEs)需至少一次减量,309例(46.4%)在无任何副作用证据的情况下减量,261例(39%)终止治疗。真实世界分析显示减量主要是作为预防措施而非因不良反应发生。

要点

  • 666例CML患者中,慢性期515例、加速期50例、急变期101例。
  • 中位随访14.4个月,136例(20.4%)因不良事件减量,309例(46.4%)无副作用证据仍减量。
  • 261例(39%)终止治疗;593例可分析患者中59%报告分子学反应。

核心结论

  • 真实世界分析显示,帕纳替尼减量主要是作为预防措施而非因不良反应发生。

研究设计与样本

  • 通过意大利药品管理局(AIFA)监测登记处进行的回顾性分析。
  • 2015年2月至2020年12月纳入帕纳替尼登记处的666例CML患者,其中慢性期515例、加速期50例、急变期101例。
  • 基线中位年龄58.7岁,男性占57.1%;从诊断至开始帕纳替尼的中位时间为2.35年。
  • 259例(38.9%)既往接受过二线治疗,260例(39.0%)三线治疗,147例(22.1%)四线及以上治疗。

主要发现

  • 593例可分析患者中,59%报告分子学反应(从主要分子学反应(MMR)至国际报告量表(IS)评分≤0.01%)。
  • 中位随访14.4个月,136例(20.4%)因不良事件(AEs)需至少一次减量,309例(46.4%)在无任何副作用证据的情况下减量。
  • 261例(39%)终止治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Real-world data on daily practice management, treatment modifications and outcome of a large cohort of chronic myeloid leukaemia (CML) patients treated with ponatinib was performed through monitoring Registries of the Italian Medicines Agency (AIFA). Overall, 666 CML subjects were included in the ponatinib registry from February 2015 to December 2020 and were eligible for analysis: 515 in chronic phase (CP), 50 in accelerated phase (AP) and 101 in blast crisis (BC). Median age at baseline was 58.7 years with a predominance of male subjects (57.1%). The median time from diagnosis to start of ponatinib was 2.35 years: 259 (38.9%) subjects had received two previous lines of treatment, 260 (39.0%) three lines and 147 (22.1%) four or more lines. A molecular response [from major molecular response (MMR) to a score of ≤0.01% on the international reporting scale (IS)] was reported for 59% of patients out of 593 patients analysed. With a median follow-up of 14.4 months, 136 subjects (20.4%) required at least one dose reduction due to adverse events (AEs), whereas 309 patients (46.4%) required dose reduction in the absence of any evidence of side effects. Treatment discontinuation occurred in 261 patients (39%). This real-life analysis shows that dose reductions were made primarily as a precaution rather than due to the occurrence of adverse reactions.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Breccia M, Olimpieri PP, Celant S, et al. Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA). Br J Haematol. 2022. PMID: 35904979. doi:10.1111/bjh.18359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。